HRP20201137T1 - Intranazalni pripravak koji sadrži betahistin - Google Patents
Intranazalni pripravak koji sadrži betahistin Download PDFInfo
- Publication number
- HRP20201137T1 HRP20201137T1 HRP20201137TT HRP20201137T HRP20201137T1 HR P20201137 T1 HRP20201137 T1 HR P20201137T1 HR P20201137T T HRP20201137T T HR P20201137TT HR P20201137 T HRP20201137 T HR P20201137T HR P20201137 T1 HRP20201137 T1 HR P20201137T1
- Authority
- HR
- Croatia
- Prior art keywords
- betahistine
- dose
- pharmaceutical preparation
- day
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Farmaceutski pripravak za intranazalnu isporuku ljudskom pacijentu, koji sadrži otopinu ili suspenziju terapijski efikasne količine betahistin dihidroklorida, sredstvo za poboljšanje viskoziteta, i pufersko sredstvo, naznačen time što je pH farmaceutskog pripravka 4.4 do 6.4.
2. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što je pH farmaceutskog pripravka 4.4, 4.8, 5, 5.2, 5.4, 5.6, 5.8, 6, 6.2, ili 6.4, ili pri čemu je pH između bilo kojih od navedenih vrijednosti.
3. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što poslije jedne intranazalne primjene čovjeku:
(i) Cmax betahistina je u opsegu od 80-125% od:
640 pg/mL za dozu od 5 mg betahistina;
2000 pg/mL za dozu od 10 mg betahistina;
4000 pg/mL za dozu od 20 mg betahistina; ili
10500 pg/mL za dozu od 40 mg betahistina; ili
(ii) AUC0-last betahistina je u opsegu od 80% -125%:
210 pg*h/mL za dozu od 5 mg betahistina;
500 pg*h/mL za dozu od 10 mg betahistina;
1600 pg*h/mL za dozu od 20 mg betahistina; ili
3500 pg*h/mL za dozu od 40 mg betahistina; ili
(iii) AUC0-inf betahistina je u opsegu od 80% -125%:
275 pg*h/mL za dozu od 5 mg betahistina;
700 pg*h/mL za dozu od 10 mg betahistina;
1630 pg*h/mL za dozu od 20 mg betahistina; ili
3940 pg*h/mL za dozu 40 mg betahistina; ili
(iv) tmax betahistina je u opsegu od 0.08-0.5 sati.
4. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što je sredstvo za poboljšanje viskoziteta odabran iz grupe koja se sastoji od polivinil pirolidona, polivinil alkohola, metilceluloze, karboksimetil celuloze-Na, hidroksietilceluloze, hidroksipropil celuloze, hidroksipropil metilceluloze, polietilen-oksida, Karbopola, polietilen glikola, propilen glikola, glicerina, alginata, karagenana, pektina, maltodekstrina, natrij škrobnog glikolata, tragakant gume, gumarabike, mikrokristalne celuloze i njihovih kombinacija.
5. Farmaceutski pripravak prema patentnom zahtjevu 4, naznačen time što je sredstvo za poboljšanje viskoziteta polivinil pirolidon.
6. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, koja dodatno sadrži jedan ili više hidratantnih sredstava; izborno naznačen time što je jedan ili više hidratantnih sredstava odabrano iz grupe koja se sastoji od glicerina, etilen glikola, propilen glikola, propilen glikola 400, heksalen glikola, butilen glikola, dekstroze, gliceril triacetata, polidekstroze, glicerola, gliceril triacetata, sorbitola, manitola, i njihovih kombinacija.
7. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što:
(i) pripravak sadrži betahistin dihidroklorid u koncentraciji od 1 mg/mL do 1000 mg/mL, ili 10 mg/mL do 400 mg/mL; ili
(ii) pripravak je u obliku jedinične doze koja sadrži betahistin dihidroklorid u količini od 5 mg do 100 mg, 5 mg, 10 mg, 20 mg, 40 mg, ili 80 mg; ili
(iii) pripravak je u obliku jedinične doze, koja sadrži 1 μL do 1000 μL pripravka po jediničnoj dozi.
8. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što pripravak:
(i) je sposoban da se primjenjuje kao sprej ili aerosol; ili
(ii) je vodena otopina; ili
(iii) sadrži lipid; ili
(iv) dodatno sadrži najmanje jedno dodatno farmaceutski aktivno sredstvo; izborno pri čemu je najmanje jedno dodatno farmaceutski aktivno sredstvo antagonist glutamatnog receptora; ili
(v) dodatno sadrži najmanje jedan inhibitor enzima ili promotor apsorpcije.
9. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što:
(i) Cmax betahistina u ljudskoj plazmi poslije jedne intranazalne doze pripravka je najmanje 0,5 ng/mL ili najmanje 4 ng/mL; ili
(ii) jedna doza pripravka sadrži 20 mg ili 40 mg betahistin dihidroklorida; ili
(iii) tmax betahistina u ljudskoj plazmi poslije jedne intranazalne doze pripravka je 0.08 h ili više ili je 0.12 h ili više; ili
(iv) AUC0-last betahistina u ljudskoj plazmi poslije jedne intranazalne doze pripravka je najmanje 0.2 h*ng/mL, najmanje 1.5 h*ng/mL, ili najmanje 3.0 h*ng/mL.
10. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-9, za uporabu kao medikament.
11. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-9, za uporabu u postupku liječenja, ublažavanja simptoma, ili za profilaksu poremećaja unutrašnjeg uha, vestibularnog poremećaja, neuro-otološkog poremećaja, otološkog poremećaja ili neurološkog poremećaja; naznačen time što se pripravak primjenjuje intranazalno, i izborno pri čemu:
(i) vestibularni poremećaj je vestibularna vrtoglavica ili Menierova bolest; ili
(ii) poremećaj unutrašnjeg uha je odabran od zujanja u ušima ili gubitka sluha; ili
(iii) poremećaj unutrašnjeg uha povezan je sa simptomima: gubitak sluha, akutni gubitak sluha, zujanje u ušima, mučnina ili nesvjestica.
12. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-9, za uporabu u postupku olakšavanja vestibularne rehabilitacije.
13. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-9, za uporabu u postupku liječenja gojaznosti, smanjenja dobivanja na težini, liječenja dobivanja na težini, i/ili liječenja poremećaja ishrane, naznačen time što se pripravak primjenjuje intranazalno; izborno gdje je dobivanje na težini inducirano primjenom antipsihotičkih lijekova koji djeluju na histaminske receptore; izborno pri čemu je antipsihotički lijek olanzapin.
14. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 10-13, naznačen time što:
(i) pripravak se primjenjuje jednom dnevno, dva puta dnevno, tri puta dnevno, četiri puta dnevno, pet puta dnevno, šest puta dnevno, sedam puta dnevno, osam puta dnevno, devet puta dnevno, ili deset puta dnevno; i/ili
(ii) ukupna dnevna doza betahistin dihidroklorida je 0.01 mg/kg do 20 mg/kg tjelesne težine ljudskog pacijenta.
15. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 10-14, naznačen time što:
(i) ukupna dnevna doza betahistin dihidroklorida je 1 do 200 mg ili je 5 do 100 mg; ili
(ii) pripravak se primjenjuje u jediničnoj dozi koja sadrži betahistin dihidroklorid, u količini od 1 mg do 100 mg betahistina po jediničnoj dozi; ili
(iii) poslije jedne intranazalne primjene čovjeku, relativna bioraspoloživost betahistina koji se isporučuje intranazalno je 10-50 puta veća u odnosu na betahistin koji se isporučuje oralno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453931P | 2017-02-02 | 2017-02-02 | |
| PCT/EP2018/052695 WO2018141922A1 (en) | 2017-02-02 | 2018-02-02 | Intranasal composition comprising betahistine |
| EP18703749.4A EP3474850B1 (en) | 2017-02-02 | 2018-02-02 | Intranasal composition comprising betahistine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201137T1 true HRP20201137T1 (hr) | 2021-01-22 |
Family
ID=61187302
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201137TT HRP20201137T1 (hr) | 2017-02-02 | 2018-02-02 | Intranazalni pripravak koji sadrži betahistin |
| HRP20231706TT HRP20231706T1 (hr) | 2017-02-02 | 2018-02-02 | Intranazalni pripravak koji sadrži betahistin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231706TT HRP20231706T1 (hr) | 2017-02-02 | 2018-02-02 | Intranazalni pripravak koji sadrži betahistin |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10456386B2 (hr) |
| EP (2) | EP3474850B1 (hr) |
| JP (3) | JP2020506930A (hr) |
| KR (1) | KR102653545B1 (hr) |
| CN (2) | CN110418643A (hr) |
| AR (1) | AR111699A1 (hr) |
| AU (1) | AU2018216970B2 (hr) |
| CA (1) | CA3051725A1 (hr) |
| CL (1) | CL2019002145A1 (hr) |
| CO (1) | CO2019008657A2 (hr) |
| DK (2) | DK3474850T3 (hr) |
| EA (1) | EA201991817A1 (hr) |
| ES (2) | ES2969301T3 (hr) |
| FI (1) | FI3698791T3 (hr) |
| HR (2) | HRP20201137T1 (hr) |
| HU (2) | HUE050829T2 (hr) |
| IL (1) | IL268353B2 (hr) |
| LT (2) | LT3698791T (hr) |
| MA (1) | MA46778B1 (hr) |
| MX (1) | MX381932B (hr) |
| MY (1) | MY196333A (hr) |
| NZ (1) | NZ755931A (hr) |
| PH (1) | PH12019501785B1 (hr) |
| PL (2) | PL3474850T3 (hr) |
| PT (2) | PT3698791T (hr) |
| RS (2) | RS60554B1 (hr) |
| SA (1) | SA519402324B1 (hr) |
| SG (1) | SG11201906980YA (hr) |
| SI (2) | SI3474850T1 (hr) |
| TN (1) | TN2019000220A1 (hr) |
| TW (1) | TWI760429B (hr) |
| WO (1) | WO2018141922A1 (hr) |
| ZA (1) | ZA201904955B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170532A1 (en) * | 2017-03-22 | 2018-09-27 | Franz, Lilian Ann | Treatment method |
| WO2021211504A1 (en) * | 2020-04-14 | 2021-10-21 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Nasal spray formulation with moisturizing benefits |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397840B1 (hr) | 1977-07-22 | 1981-03-20 | Cherqui Jean | |
| IT1229237B (it) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | Sali di (2-(piridil)etil) metilammina |
| JPH03287535A (ja) * | 1990-03-31 | 1991-12-18 | Bairon Boeki Kk | プラノプロフェン水溶液 |
| JP3203056B2 (ja) * | 1992-08-13 | 2001-08-27 | 株式会社ティ・ティ・エス技術研究所 | メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤 |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| JPH10139667A (ja) * | 1996-11-15 | 1998-05-26 | Yoshitomi Pharmaceut Ind Ltd | 水性液剤 |
| EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP3555598B2 (ja) | 2001-06-27 | 2004-08-18 | 株式会社村田製作所 | 積層型インダクタ |
| JP2004196676A (ja) * | 2002-12-16 | 2004-07-15 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
| JP4733333B2 (ja) * | 2002-12-26 | 2011-07-27 | ライオン株式会社 | 点鼻剤又は洗鼻剤 |
| ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| KR20060134041A (ko) | 2004-04-22 | 2006-12-27 | 모르 리서치 애플리케이션즈 리미티드 | 음식물 섭취 관리 방법 |
| AU2006202950A1 (en) * | 2004-04-22 | 2006-10-19 | Mor Research Applications Ltd. | Methods and Compositions for Weight Management |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| EP2457580A1 (en) | 2004-08-25 | 2012-05-30 | The UAB Research Foundation | Absorption enhancers for drug administration |
| US20070111964A1 (en) * | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
| WO2007076140A2 (en) * | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| WO2009086055A1 (en) * | 2007-12-21 | 2009-07-09 | Schering-Plough Healthcare Products, Inc. | Enhancing photostabilization of oxymetazoline |
| KR20130097813A (ko) * | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| JP5543963B2 (ja) * | 2008-05-27 | 2014-07-09 | ザ ユニバーシティー オブ メルボルン | エウスタキオ管機能障害を有する哺乳動物の治療方法 |
| CN102216257B (zh) * | 2008-10-08 | 2015-11-25 | 凯飞药业公司 | Gaba偶联物及其使用方法 |
| PL3200828T3 (pl) * | 2014-10-03 | 2021-01-25 | Lachesis Biosciences Limited | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych |
-
2018
- 2018-02-02 ES ES20170448T patent/ES2969301T3/es active Active
- 2018-02-02 HR HRP20201137TT patent/HRP20201137T1/hr unknown
- 2018-02-02 AR ARP180100254A patent/AR111699A1/es unknown
- 2018-02-02 SG SG11201906980YA patent/SG11201906980YA/en unknown
- 2018-02-02 EP EP18703749.4A patent/EP3474850B1/en active Active
- 2018-02-02 FI FIEP20170448.3T patent/FI3698791T3/fi active
- 2018-02-02 JP JP2019541717A patent/JP2020506930A/ja active Pending
- 2018-02-02 DK DK18703749.4T patent/DK3474850T3/da active
- 2018-02-02 PT PT201704483T patent/PT3698791T/pt unknown
- 2018-02-02 RS RS20200851A patent/RS60554B1/sr unknown
- 2018-02-02 MX MX2019008961A patent/MX381932B/es unknown
- 2018-02-02 LT LTEP20170448.3T patent/LT3698791T/lt unknown
- 2018-02-02 HU HUE18703749A patent/HUE050829T2/hu unknown
- 2018-02-02 IL IL268353A patent/IL268353B2/en unknown
- 2018-02-02 EP EP20170448.3A patent/EP3698791B1/en active Active
- 2018-02-02 US US15/887,388 patent/US10456386B2/en active Active
- 2018-02-02 ES ES18703749T patent/ES2807798T3/es active Active
- 2018-02-02 PH PH1/2019/501785A patent/PH12019501785B1/en unknown
- 2018-02-02 PL PL18703749T patent/PL3474850T3/pl unknown
- 2018-02-02 SI SI201830082T patent/SI3474850T1/sl unknown
- 2018-02-02 HU HUE20170448A patent/HUE065336T2/hu unknown
- 2018-02-02 LT LTEP18703749.4T patent/LT3474850T/lt unknown
- 2018-02-02 PT PT187037494T patent/PT3474850T/pt unknown
- 2018-02-02 DK DK20170448.3T patent/DK3698791T3/da active
- 2018-02-02 CN CN201880017726.2A patent/CN110418643A/zh active Pending
- 2018-02-02 WO PCT/EP2018/052695 patent/WO2018141922A1/en active IP Right Grant
- 2018-02-02 AU AU2018216970A patent/AU2018216970B2/en active Active
- 2018-02-02 TW TW107103800A patent/TWI760429B/zh active
- 2018-02-02 PL PL20170448.3T patent/PL3698791T3/pl unknown
- 2018-02-02 EA EA201991817A patent/EA201991817A1/ru unknown
- 2018-02-02 SI SI201831043T patent/SI3698791T1/sl unknown
- 2018-02-02 MY MYPI2019004366A patent/MY196333A/en unknown
- 2018-02-02 RS RS20240022A patent/RS65099B1/sr unknown
- 2018-02-02 NZ NZ755931A patent/NZ755931A/en unknown
- 2018-02-02 TN TNP/2019/000220A patent/TN2019000220A1/en unknown
- 2018-02-02 MA MA46778A patent/MA46778B1/fr unknown
- 2018-02-02 KR KR1020197025622A patent/KR102653545B1/ko active Active
- 2018-02-02 CA CA3051725A patent/CA3051725A1/en active Pending
- 2018-02-02 HR HRP20231706TT patent/HRP20231706T1/hr unknown
- 2018-02-02 CN CN202410176958.XA patent/CN118356397A/zh active Pending
-
2019
- 2019-07-26 SA SA519402324A patent/SA519402324B1/ar unknown
- 2019-07-29 ZA ZA2019/04955A patent/ZA201904955B/en unknown
- 2019-07-30 CL CL2019002145A patent/CL2019002145A1/es unknown
- 2019-08-09 CO CONC2019/0008657A patent/CO2019008657A2/es unknown
- 2019-09-13 US US16/570,156 patent/US20200022963A1/en not_active Abandoned
-
2022
- 2022-02-08 JP JP2022017792A patent/JP2022051872A/ja not_active Withdrawn
-
2024
- 2024-01-04 JP JP2024000158A patent/JP2024019731A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2607892C2 (ru) | Композиции на основе ксилита, препятствующие отделению слизи, а также смежные способы и композиции | |
| US6599883B1 (en) | Nasal delivery of xylitol | |
| FI3668509T3 (fi) | Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20120798T1 (hr) | Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| WO2014020155A1 (en) | Oral transmucosal adminstration forms of s-ketamine | |
| KR20110045004A (ko) | 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물 | |
| WO2006017505A3 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
| HRP20201137T1 (hr) | Intranazalni pripravak koji sadrži betahistin | |
| CA2522291A1 (en) | Nasal pharmaceutical formulations and methods of using the same | |
| US12233066B2 (en) | Combinations of inhibitors of influenza virus replication | |
| JP2007530620A (ja) | メロキシカムを含む組成物 | |
| CN101396364B (zh) | 扎来普隆口腔给药系统或组合物及其制备方法 | |
| JP2020506930A5 (hr) | ||
| JP2009539893A (ja) | 組合せウェーハ | |
| JP5828007B2 (ja) | 局所投与型の嚥下障害改善用医薬品 | |
| CN110833540B (zh) | 一种柳酚咖敏片及其制备方法 | |
| KR20190009294A (ko) | 비강 울혈을 치료/예방하기 위한 카르복실산 | |
| US20090124606A1 (en) | Composition for Treatment of Psychosis | |
| RU2005121130A (ru) | Применение левоцетиризина для лечения устойчивого аллергического ринита | |
| MX2024004372A (es) | Formulacion oral. | |
| CA3224519A1 (en) | Compositions and methods for treating and preventing viral infections | |
| WO2020180279A1 (ru) | Фармацевтическая композиция для интраназального введения | |
| HK40049091A (en) | Combinations of inhibitors of influenza virus replication |